Nothing Special   »   [go: up one dir, main page]

MX2024001659A - Composiciones y métodos para el tratamiento de la sobredosis por opioides. - Google Patents

Composiciones y métodos para el tratamiento de la sobredosis por opioides.

Info

Publication number
MX2024001659A
MX2024001659A MX2024001659A MX2024001659A MX2024001659A MX 2024001659 A MX2024001659 A MX 2024001659A MX 2024001659 A MX2024001659 A MX 2024001659A MX 2024001659 A MX2024001659 A MX 2024001659A MX 2024001659 A MX2024001659 A MX 2024001659A
Authority
MX
Mexico
Prior art keywords
methods
compositions
treatment
opioid overdose
drug products
Prior art date
Application number
MX2024001659A
Other languages
English (en)
Inventor
Phil Skolnick
Roger Crystal
Mark Ellison
Original Assignee
Indivior Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indivior Inc filed Critical Indivior Inc
Publication of MX2024001659A publication Critical patent/MX2024001659A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan productos farmacólogicos adaptados para administración nasal, que comprenden un dispositivo precebado lleno con una composición farmacéutica que comprende nalmefeno. También se proporcionan métodos para el tratamiento de sobredosis por opioides con los productos farmacológicos.
MX2024001659A 2021-08-04 2022-08-04 Composiciones y métodos para el tratamiento de la sobredosis por opioides. MX2024001659A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163229300P 2021-08-04 2021-08-04
PCT/US2022/039463 WO2023014906A1 (en) 2021-08-04 2022-08-04 Compositions and methods for the treatment of opioid overdose

Publications (1)

Publication Number Publication Date
MX2024001659A true MX2024001659A (es) 2024-06-26

Family

ID=85156443

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024001659A MX2024001659A (es) 2021-08-04 2022-08-04 Composiciones y métodos para el tratamiento de la sobredosis por opioides.

Country Status (7)

Country Link
US (1) US20230055547A1 (es)
EP (1) EP4380570A1 (es)
AU (1) AU2022323269A1 (es)
CA (1) CA3227828A1 (es)
IL (1) IL310566A (es)
MX (1) MX2024001659A (es)
WO (1) WO2023014906A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9918559D0 (en) * 1999-08-07 1999-10-06 Glaxo Wellcome Kk Novel pharmaceutical formulation
US20180000942A1 (en) * 2013-12-18 2018-01-04 Aegis Therapeutics, Llc Compositions for drug administration
EP3082816B1 (en) * 2013-12-20 2019-03-20 Indivior UK Limited Intranasal naloxone compositions and methods of making and using same
US9480644B2 (en) * 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
EP3538189A4 (en) * 2016-11-09 2020-04-22 Opiant Pharmaceuticals, Inc. COMPOSITIONS, DEVICES AND METHODS FOR TREATING OPIOID RECEPTOR-MEDIATED STATES
IL312012A (en) * 2016-11-18 2024-06-01 Opiant Pharmaceuticals Inc Preparations and methods for treating an opioid overdose
US20200390691A1 (en) * 2018-12-20 2020-12-17 Aegis Therapeutics, Inc. Compositions, devices, and methods for the treatment of overdose and reward-based disorders

Also Published As

Publication number Publication date
AU2022323269A1 (en) 2024-02-29
IL310566A (en) 2024-03-01
CA3227828A1 (en) 2023-02-09
WO2023014906A1 (en) 2023-02-09
EP4380570A1 (en) 2024-06-12
US20230055547A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
IL286539A (en) A pharmaceutical preparation containing human hyaluronidase ph20 variant and a drug for subcutaneous administration
PH12018502738A1 (en) Compositions, devices, and methods for the treatment of alcohol use disorder
GB2538682A (en) Nasal drug products and methods of their use
RS52831B (en) THIN BUPRENORPHINE TILES FOR DRUG REPLACEMENT THERAPY
HK1139871A1 (en) Improvements in and relating to medicinal compositions
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
NZ588913A (en) Liver cancer drug
DK3962455T3 (en) New pharmaceutical composition for drug delivery
WO2018188797A8 (en) Dispensing cap containing a solubilisate of a pharmaceutically active agent or dietary supplement
ZA202302155B (en) Interferon-based cancer treatment method and pharmaceutical composition
NZ769954A (en) Syringe devices for use in an emergency
EP3962661A4 (en) NASAL MEDICATION DELIVERY DEVICES AND METHODS
MX2007005065A (es) Forma de dosis de tiempo de retraso de farmacos para la terapia de insomnio.
MX2023012465A (es) Regimen de dosificacion de anti-ifnar1 para inyeccion subcutanea.
MX2021004883A (es) Metodos y composiciones para tratar apnea del sue?o.
MX2024001659A (es) Composiciones y métodos para el tratamiento de la sobredosis por opioides.
MX2021007522A (es) Composiciones, dispositivos y metodos para el tratamiento de trastornos por sobredosis y basados en recompensas.
MX2019010086A (es) Esquema de dosificacion para una combinacion de ceritinib y una molecula de anticuerpo anti-pd-1.
MX2018003349A (es) Productos de farmaco nasal y metodos de su uso.
MX2020006886A (es) Sistema para suministro de medicamento.
CA231027S (en) Drug delivery device
GB202104970D0 (en) Drug delivery device and method
GB202305255D0 (en) Drug delivery device and method
GB202204944D0 (en) Drug delivery device and method
GB202003083D0 (en) Drug delivery device and method